Protagonist Therapeutics Reports Third-Quarter Revenue of $274.4 Million and Net Income of $220.0 Million
Third-quarter 2026 diluted earnings per share were $3.07, versus a loss of $0.62 per share a year earlier. Revenue was $4.7 million and net loss was $39.3 million in the prior-year quarter.
Protagonist Therapeutics reported third-quarter 2026 revenue of $274.4 million and net income of $220.0 million, compared with revenue of $4.7 million and a net loss of $39.3 million a year earlier. Diluted earnings per share were $3.07, versus a loss of $0.62 per share in the prior-year quarter. T…